Vifor Pharma AG Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 7/26/2022)
| Balance Sheet | Total Assets | 5,099,600,000.00 | ROE | – |
| Balance Sheet | Total Equity | 3,489,900,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -218,700,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 308,700,000.00 | – | – |
| Cashflow | Operating Cash Flow | 527,400,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.22 | Div. Yield | – |
| Income | Net Income | 144,400,000.00 | P/E | – |
| Income | Shares Outstanding | 64,864,300.00 | P/B | – |
| Income | Total Revenue | 1,824,600,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD). It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; Veltassa for the treatment of hyperkalaemia in CKD and chronic heart failure patients; and Invokana to treat diabetic kidney disease. Further, it developing Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases; ANG-3777 for the treatment of delayed graft function and cardiac surgery-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1872 and is headquartered in Sankt Gallen, Switzerland.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.viforpharma.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more